featured
Long-Term Outcomes After Perioperative Chemotherapy and Nivolumab for NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial
Lancet Oncol 2024 Oct 14;[EPub Ahead of Print], M Provencio, E Nadal, A Insa, R García Campelo, J Casal, M Dómine, B Massuti, M Majem, D Rodríguez-Abreu, A Martínez-Martí, J de Castro, D Gómez de Antonio, I Macia, S Figueroa, L Fernández Vago, V Calvo, R Palmero, B Sierra-Rodero, C Martínez-Toledo, M Molina-Alejandre, R Serna-Blasco, A Romero, A Cruz-BermúdezFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.